Pathological response in resectable non–small cell lung cancer: a systematic literature review and meta-analysis
Open Access
- 23 March 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (3)
Abstract
Surrogate endpoints for overall survival in patients with resectable non–small cell lung cancer receiving neoadjuvant therapy are needed to provide earlier treatment outcome indicators and accelerate drug approval. This study’s main objectives were to investigate the association among pathological complete response, major pathological response, event-free survival and overall survival and to determine whether treatment effects on pathological complete response and event-free survival correlate with treatment effects on overall survival. A comprehensive systematic literature review was conducted to identify neoadjuvant studies in resectable non–small cell lung cancer. Analysis at the patient level using frequentist and Bayesian random effects (hazard ratio [HR] for overall survival or event-free survival by pathological complete response or major pathological response status, yes vs no) and at the trial level using weighted least squares regressions (hazard ratio for overall survival or event-free survival vs pathological complete response, by treatment arm) were performed. In both meta-analyses, pathological complete response yielded favorable overall survival compared with no pathological complete response (frequentist, 20 studies and 6530 patients: HR = 0.49, 95% confidence interval = 0.42 to 0.57; Bayesian, 19 studies and 5988 patients: HR = 0.48, 95% probability interval = 0.43 to 0.55) and similarly for major pathological response (frequentist, 12 studies and 1193 patients: HR = 0.36, 95% confidence interval = 0.29 to 0.44; Bayesian, 11 studies and 1018 patients: HR = 0.33, 95% probability interval = 0.26 to 0.42). Across subgroups, estimates consistently showed better overall survival or event-free survival in pathological complete response or major pathological response compared with no pathological complete response or no major pathological response. Trial-level analyses showed a moderate to strong correlation between event-free survival and overall survival hazard ratios (R2 = 0.7159) but did not show a correlation between treatment effects on pathological complete response and overall survival or event-free survival. There was a strong and consistent association between pathological response and survival and a moderate to strong correlation between event-free survival and overall survival following neoadjuvant therapy for patients with resectable non–small cell lung cancer.Keywords
Funding Information
- Bristol Myers Squibb
This publication has 80 references indexed in Scilit:
- Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic reviewThe Lancet, 2007
- Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2007
- The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancerLung Cancer, 2003
- Radiotherapy Versus Chemotherapy plus Radiotherapy in Surgically Treated IIIA N2 non—small-Cell Lung CancerClinical Lung Cancer, 2002
- Long-Term Results of Combined-Modality Therapy in Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- Preoperative Chemotherapy Followed by Surgery Compared With Primary Surgery in Resectable Stage I (Except T1N0), II, and IIIa Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2002
- A Randomized Trial Comparing Perioperative Chemotherapy and Surgery With Surgery Alone in Resectable Stage IIIA Non-Small-Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1994
- A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung CancerNew England Journal of Medicine, 1994
- Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma results from a randomized phase II trialCancer, 1990